All posts by Mary Jo Strobel

In My Shoes: Courageous ill child is inspiring

No one expects a healthy child to develop an incurable disease. I know I didn’t.

Like any first-time mother, I was excited when Joshua first started eating solid food. He readily downed diced carrots, peas, bananas and potatoes.

But when he reached 10 months, mealtime became mayhem. He resisted, gagged on and vomited basic foods. Reading baby books calmed my nervousness. It was just a little spit up, right?

But the gagging worsened. I painfully watched him lose the ability to swallow even a teaspoon of pureed food. Eating became dreaded and painful for Joshua, my husband and me. We held our breath when he swallowed, praying the food would stay down. He needed the nutrients. What else could we do?

Joshua also developed problems with breathing and became allergic to grass, pollen and trees. He apparently inherited my asthma gene. Round-the-clock nebulizer treatments seemed excessive and did not really help his wheezing.

When I returned to the workforce after his first birthday, I felt an inner struggle. I worried about whether a caregiver would be as sensitive as I was to his wheezing and flare-ups.

At the onset of symptoms, I grabbed Joshua’s emergency room bag and a carryout dinner for the all-expense-paid trip to the emergency room. This, not the career fast lane, became normal.

Another family gene, eczema, also took over his innocent body. Perpetual scratching led to pulling his hair out.

Lathering him with ointments and oils only modestly helped improve his dry skin. Doctors prescribed steroid creams that helped slightly. But how would steroid medication affect his growth?

We saw these ailments, and doctors treated them, as separate complaints. By this point, Joshua tolerated only a handful of “safe” foods and continued to fall behind his age group on weight gain.

I literally became Dr. Google, moonlighting on medical websites and trying to find answers about his overlapping conditions.

My sleuthing paid off when I stumbled across a disease that included allergies, eczema and vomiting. Since the most pressing condition was Joshua’s inability to swallow, I sought out a gastroenterologist.

Within days, he performed a biopsy and diagnosed Joshua with eosinophilic esophagitis. Known as EOE, this disease cripples the immune system. Infection-fighting white blood cells called eosinophils attack the body and the esophagus. Having EOE means that Joshua is allergic to most food. This results in swelling and irritation throughout his gastrointestinal tract.

Other manifestations include the eczema and allergies. Researchers do not know what causes EOE. While it does not appear to be genetic, some predetermining factors are asthma and allergies.

Joshua started a liquid amino acid-based formula, Neocate, considered a standard nutrient for those diagnosed with EOE. In more severe cases, doctors recommend feeding-tube therapy. Joshua is still under evaluation for a feeding tube.

I was relieved to know that Joshua’s condition had a name. At the same time, I was overwhelmed that he had a disease with no boundaries or cure.

In addition to the daily unexpected symptoms of EOE, what concerns me is that children elsewhere may suffer from these ailments and not know it.

Joshua is now 2, and his courage inspires me. Despite his three-page résumé of medical terminology, reactions, medications and hospitalizations, and more than a dozen caregivers, he powers through it.

And that for me is food for thought.

Dawn McCoy of Chesterfield County is a writer and consultant.

– Dawn McCoy (source richmond.com)

APFED’s Hope on the Horizon Walks

Proceeds from all APFED’s Hope on the Horizon Walks will support APFED’s Hope on the Horizon Research Fund, which provides grants to investigators to pursue unique research ideas that could lead to less invasive diagnostic measures and more effective treatments for those suffering from eosinophil associated diseases. Click here to learn more about HOPE grant recipients and their research projects.


Join us May 21, 2016 in St. Louis, Missouri for APFED’s HOPE on the Horizon Walk.
Location: Tilles Park and the Gloria Rogers Shelter 

More Info and Registration Coming Soon!

Additional questions? Email jforrest@apfed.org


 

Join us May 21, 2016 in Kingsville, MD for APFED’s HOPE on the Horizon Walk.
NEW LOCATION

Historic Jerusalem Mill Village
2813 Jerusalem Road
Kingsville, MD 21087
9AM – Noon
More Info and Registration Coming Soon

Additional questions? Email jforrest@apfed.org


 

APFED’s Hope on the Horizon Virtual Walk
No Hope on the Horizon Walk in your area? You can still get involved and support research of eosinophil associated diseases by participating in our Virtual Walk!

More Info
Register Online
Pledge Form
Donate

Smoking is prohibited at this event. For event notices and information, visit our Walk Facebook page at https://www.facebook.com/HopeOnTheHorizonWalks.

Interested in SPONSORING or HOSTING one of APFED’s Hope on the Horizon Walks?
Please contact fundraise@apfed.org for more information.

Patient Advocacy Groups Unite in Support of Those with Eosinophil-Associated Diseases

New Coalition Launches during National Eosinophil Awareness Week
(Atlanta, GA)  — To support patients of eosinophil-associated diseases and to advance key issues of importance to this population, patient advocacy groups from around the world have united together to form the Coalition of Eosinophil Patient Advocacy Groups (C-EOS). 
 
The mission of C-EOS is two-fold:
· To encourage, promote, and support scientific research toward improved treatment, medical care, and cures of eosinophil-associated diseases and their complications.
 
· To educate the public, patients, families, policymakers, healthcare professionals, and other stakeholders about eosinophil-associated diseases and resulting problems for these patients, including the need for better diagnostic testing, further research for treatments, and a cure.
Eosinophil-associated diseases occur when levels of eosinophils, a type of white blood cell, are elevated in certain areas of the body. Eosinophils play an important role in the immune system, helping to fight off certain types of infections and parasites. These cells respond to triggers, such as food or airborne allergens, by releasing toxins into the affected area. The diagnosis depends on where the eosinophils cause damage. Subsets include eosinophilic gastrointestinal disorders (esophagus, stomach, or intestines); eosinophilic granulomatosis with polyangiitis, aka Churg-Strauss Syndrome, (lungs, sinuses, heart, and various organ systems); and hypereosinophilic syndrome (blood and organs).
 
Eosinophilic gastrointestinal disorders often render the patient unable to tolerate certain food proteins. Treatments for these disorders include restricted diets or total food elimination, requiring patients to live off an elemental formula (taken either orally or via a feeding tube), and/or steroid treatments.
 
Due to the lack of information or awareness of these diseases, patients suffer for years trying to obtain an accurate diagnosis and appropriate treatment.  Although not commonly life-threatening, these chronic diseases require lifelong treatment and can cause debilitating symptoms.  There is no cure and no FDA-approved treatments.
 
“Eosinophil-associated diseases are chronic, rare diseases that significantly impact quality of life,” said Mary Jo Strobel, Executive Director for the American Partnership for Eosinophilic Disorders, a C-EOS participant. “As an organization dedicated to serving patients and families who live with these diseases, we are thrilled to join C-EOS and are excited to see so many organizations work together in support of patients and researchers who are paving the way to a cure." 
 
C-EOS launches during National Eosinophil Awareness Week, May 18-24. For more information about the coalition and to see other participating organizations, please visit www.c-eos.org.

About American Partnership for Eosinophilic Disorders (APFED)

American Partnership for Eosinophilic Disorders (APFED) is a non-profit organization dedicated to patients and their families coping with eosinophilic disorders. APFED’s mission is to passionately embrace, support, and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support, and advocacy. www.apfed.org

APFED Celebrates National Eosinophil Awareness Week May 18-24, 2014

Imagine having a rare disease that causes your esophagus to swell and narrow, preventing you from eating any food. Or one that causes inflammation and damage to your skin, lungs, heart, or nervous system. Imagine having a disease that causes bone pain, muscle pain, and thickened, puckered skin and not being able to find a doctor who is able to help. These diseases aren’t imaginary – eosinophil-associated diseases are real, they are rare, and they are growing in prevalence.

Eosinophil-associated diseases occur when levels of eosinophils, a type of white blood cell, are elevated in certain areas of the body. Eosinophils play an important role in the immune system, helping to fight off certain types of infections and parasites. These cells respond to triggers (e.g., food and airborne allergens) by releasing toxins into the affected area. The diagnosis depends on where the eosinophils cause damage. Subsets include eosinophilic gastrointestinal disorders (affects esophagus, stomach, or intestines); eosinophilic granulomatosis with polyangiitis, aka Churg-Strauss Syndrome, (affects lungs, sinuses, heart, and various organ systems); and hypereosinophilic syndrome (affects blood and organs).

Eosinophilic gastrointestinal disorders often render the patient unable to tolerate certain food proteins. Treatments for these disorders include restricted diets or total food elimination, requiring patients to live off an elemental formula (taken either orally or via a feeding tube), and/or steroid treatments.

The American Partnership for Eosinophilic Disorders (APFED) will celebrate the 7th annual National Eosinophil Awareness Week May 18- May 24 by uniting patients, families, patient advocacy groups, medical institutions, medical societies, physicians, and companies that support those who have eosinophil-associated diseases in effort to create awareness and educate the public and the medical community about these diseases.

“Eosinophil-associated diseases are rare diseases, but are emerging as a worldwide health care problem,” said APFED Executive Director Mary Jo Strobel. “There is no better time than National Eosinophil Awareness Week for patients, caregivers, organizations, and health care providers to work together in a united effort to raise awareness about what these diseases are and what it is like to live with them.”

Due to the lack of information or awareness of these diseases, patients suffer for years trying to obtain an accurate diagnosis and appropriate treatment. Although not commonly life-threatening, these chronic diseases require lifelong treatment and can cause debilitating symptoms. There is no cure and no FDA-approved treatments.

“These diseases affect people of all ages and have a significant impact on one’s quality of life,” shares APFED’s President Dr. Wendy Book. “By educating the public and health care providers, we can reduce delays in diagnosis. We are funding critical research that will lead to noninvasive testing and treatments for these diseases.”

Organizations, healthcare providers, and institutions around the globe are joining APFED to recognize National Eosinophil Awareness Week by sharing information with their communities and with the public. Nutricia, the makers of Neocate®, a line of amino acid-based products, has partnered with APFED for its celebration of this special week by providing the means for the organization to distribute educational packets to health care providers and awareness materials to the public.

Visit apfed.org to learn more about eosinophil-associated diseases and research being conducted, or for a listing of community events that are taking place during National Eosinophil Awareness Week.

About American Partnership for Eosinophilic Disorders (APFED)
American Partnership for Eosinophilic Disorders (APFED) is a non-profit organization dedicated to patients and their families coping with eosinophilic disorders. APFED’s mission is to passionately embrace, support, and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support, and advocacy. www.apfed.org

Organizations, Groups, and Healthcare Providers Celebrating National Eosinophil Awareness Week:
Alabama Eosinophilic Disorders Support Group; American Partnership for Eosinophilic Disorders; ausEE (Australia); Central Virginia EOS Support Group; Charlotte Supports EOS; Cincinnati Center for Eosinophilic Disorders/Cincinnati Children’s Hospital Medical Center; Families Affected by Eosinophilic Disorders (UK); Food Allergy & Anaphylaxis Connection Team; Food Allergy Research & Education; Matthew Greenhawt, MD, University of Michigan Food Allergy Center; Greenville Spartanburg Eos Support Group; International Association for Food Protein Enterocolitis; Kids with Food Allergies; Washington DC Area Eosinophilic Connection

Recipient of the 2014 Hope Pilot Grant Award Announced

3/26/14
Funded study to explore signaling pathway of certain cells in eosinophilic esophagitis
A promising research study that will focus on an innovative approach to define the underlying mechanism of the development of EoE has been awarded anAPFED HOPE Pilot Research Grant award .
Eosinophilic esophagitis (EoE) is a rare disease that is increasing in prevalence. It is characterized by having above normal amounts of eosinophils, a type of white blood cell, in the esophagus lining (the tube connecting the mouth to the stomach), causing inflammation and damage. EoE is a chronic condition and there is no cure.
Joanne Masterson, PhD, of University of Colorado Denver and Children’s Hospital Colorado, was announced as recipient of a $50,000 for her project tilted, “ HIF signaling and mucosal healing in EoE”. Dr. Masterson’s research will provide a greater understanding of the signaling pathway of certain cells involved with EoE as they relate to inflammation caused by oxygen deficiency in cells and tissue. Her research will help determine whether or not this signaling mediates a critical link between conditions that cause inflammation and how the mucosal tissue heals after it is damaged by EoE.
“Dr. Masterson’s research will be a valuable contribution to the research of eosinophil-associated diseases,” said APFED Executive Director Mary Jo Strobel. “Currently, there are no FDA-approved treatments for EoE. Symptoms are controlled through diet and steroids. Gaining a better understanding of the mechanisms that contribute to a cell’s involvement in EoE could lead us to new ways to treat this disease.”
APFED’s competitive research grant program, the Hope on the Horizon Research Fund, is supported entirely by donations and has contributed more than $1.6 million for the research of eosinophil-associated diseases since the fund began in 2005. HOPE Pilot awards allow investigators from a variety of disciplines to initiate new projects relevant to eosinophil-associated diseases, with a focus on the development of new ideas which are likely to lead to future external funding.
For more information about eosinophil-associated diseases and the projects that the Hope on the Horizon Research Fund has supported, visit www.apfed.org.
About American Partnership for Eosinophilic Disorders (APFED)
American Partnership for Eosinophilic Disorders (APFED) is a non-profit organization whose mission is to passionately embrace, support, and improve the lives of patients and families affected by eosinophil-associated diseases through education and awareness, research, support, and advocacy. www.apfed.org